Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 10/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893656 | 0.89 | MDM2 (0.63) | MDM2ABL1RIPK1GRM5NOTUM | |
| SCHEMBL9893845 | 0.86 | MDM2 (0.79) | MDM2NOTUM | |
| SCHEMBL9894004 | 0.86 | MDM2 (0.67) | MDM2ABL1NOTUM | |
| SCHEMBL1437232 | 0.84 | MDM2 (0.61) | MDM2 | |
| SCHEMBL1441668 | 0.80 | MDM2 (0.56) | MDM2RIPK1HTR2AHTR2CSLC6A4 | |
| SCHEMBL1437029 | 0.80 | MDM2 (0.56) | MDM2RIPK1GRM5HTR2AHTR2C | |
| SCHEMBL9893721 | 0.78 | MDM2 (0.80) | MDM2RIPK1GRM5NOTUMCHRNA7 | |
| SCHEMBL1445194 | 0.78 | MDM2 (0.73) | MDM2RIPK1PDE4APDE4BPDE4C | |
| SCHEMBL9893680 | 0.76 | MDM2 (0.52) | MDM2NOTUM | |
| SCHEMBL27862822 | 0.76 | MDM2 (0.52) | MDM2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885ABL1 340/4885RIPK1 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.